Trials / Withdrawn
WithdrawnNCT03005015
Lenvatinib in Second Line Endometrial Carcinoma
A Randomized Phase II Study of Lenvatinib Versus Doxorubicin in Second Line Advanced or Recurrent Endometrial Carcinoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Network
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer. The main secondary objective is to evaluate the predictive value of Ang-2 on lenvatinib activity and establishing a cutoff value as potential selection criteria for phase III. Other secondary objectives are to assess the tolerability and safety of lenvatinib in this setting and overall survival, response and disease control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lenvatinib | |
| DRUG | Doxorubicin |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-07-01
- First posted
- 2016-12-29
- Last updated
- 2016-12-29
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT03005015. Inclusion in this directory is not an endorsement.